Performance characteristics of the cavidi exavir viral load assay and the ultra-sensitive P24 assay relative to the roche monitor HIV-1 RNA assay

Journal of Clinical Virology

Volumn 49, Issue 3, 2010, Pages 198-204

  Stewart, Paul ^a,e   Cachafeiro, Ada ^a,e   Napravnik, Sonia ^b,e   Eron, Joseph J ^b,e   Frank, Ian ^c,e   van der Horst, Charles ^b,e   Bosch, Ronald J ^d,e   Bettendorf, Daniel ^d,e   Bohlin, Peter ^d,e   Fiscus, Susan A ^b,e  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e Adult AIDS Clinical Trials Group (AACTG)   (United States)

Author keywords

Cavidi; P24 antigen; Resource limited setting; Viral load

Indexed keywords

RNA DIRECTED DNA POLYMERASE;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOASSAY; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VIRUS LOAD;

HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 77957653638     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.07.022     Document Type: Article

References (36)

1. Braun J., Plantier J.C., Hellot M.F., Tuaillon E., Gueudin M., Damond F., et al. A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS 2003, 17:331-336.
2. Ekstrand D.H., Awad R.J., Kallander C.F., Gronowitz J.S. A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier bound template and non radioactive product detection, with special reference to human immunodeficiency virus isolation. Biotechnol Appl Biochem 1996, 23(Pt. 2):95-105.
3. Greengrass V.L., Turnbull S.P., Hocking J., Dunne A.L., Tachedjian G., Corrigan G.E., et al. Evaluation of a low cost reverse transcriptase assay for plasma HIV 1 viral load monitoring. Curr HIV Res 2005, 3:183-190.
4. Greengrass V.L., Plate M.M., Steele P.M., Denholm J.T., Cherry C.L., Morris L.M., et al. Evaluation of the Cavidi ExaVir Load assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring. J Clin Microbiol 2009, 47(9):3011-3013.
5. Greengrass V.L., Lohman B., Morris L.M., Plate M.M., Steele P.M., Walson J.L., et al. Assessment of the low-cost Cavidi ExaVir load assay for monitoring HIV viral load in pediatric and adult patients. J Acquir Immune Defic Syndr 2009, 52(3):387-390.
6. Hosseinipour M., Cachafeiro A., Namakwa D., Gama S., Joaki G., Kanyama C., et al. Comparison of the Cavidi Exavir reverse transcriptase assay to HIVRNA among antiretroviral patients in Malawi. The 3rd IAS conference on HIV pathogenesis and treatment 2005.
7. Iqbal H.S., Balakrishnan P., Cecelia A.J., Solomon S., Kumarasamy N., Madhavan V., et al. Use of an HIV 1 reverse transcriptase enzyme activity assay to measure HIV 1 viral load as a potential alternative to nucleic acid based assay for monitoring antiretroviral therapy in resource limited settings. J Med Microbiol 2007, 56:1611-1614.
8. Jennings C., Fiscus S.A., Crowe S.M., Danilovic A.D., Morack R.J., Scianna S., et al. Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol 2005, 43:5950-5956.
9. Labett W., Garcia-Diaz A., Fox Z., Clewley G.S., Fernandez T., Johnson M., et al. Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load. J Clin Microbiol 2009, 47:3266-3270.
10. Malmsten A., Shao X.W., Aperia K., Corrigan G.E., Sandstrom E., Kallander C.F., et al. HIV 1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 2003, 71:347-359.
11. Malmsten A., Shao X.W., Sjodahl S., Fredriksson E.L., Pettersson I., Leitner T., et al. Improved HIV 1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 2005, 76:291-296.
12. Mine M., Bedi K., Maruta T., Madziva D., Tau M., Zana T., et al. Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a decentralization pilot study. J Virol Methods 2009, 159(1):93-97.
13. Sivapalasingam S., Essajee S., Nyamb P.N., Itri V., Hanna B., Holzman R., et al. Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource limited settings. J Clin Microbiol 2005, 43:3793-3796.
14. Sivapalasingham S., Wangechi B., Marshed F., Laverty M., Essajee S., Holzman R.S., et al. Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low cost viral load assay. PLoS One 2009, 4:e6828.
15. Steegen K., Luchters S., DeCabooter N., Reynaerts J., Mandaliya K., Plum J., et al. Evaluation of two commercially available alternatives for HIV 1 viral load testing in resource limited settings. J Virol Methods 2007, 146:178-187.
16. Stevens G., Rekhviashvili N., Scott L.E., Gonin R., Stevens W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C infected patients from South Africa. J Clin Microbiol 2005, 43:857-861.
17. van Rooijen L.B., Greengrass V., Morris L.M., Plate M.M., Gouillou M., Tachedjian G., et al. Effect of reverse transcriptase inhibitors and mutations on the low cost Cavidi reverse transcriptase viral load assay. J Acquir Immune Defic Syndr 2009, 52:527-529.
18. Boni J., Opravil M., Tomasik Z., Rothen M., Bisset L., Grob P.J., et al. Simple monitoring of antiretroviral therapy with a signal amplification boosted HIV-1 p24 antigen assay with heat denatured plasma. AIDS 1997, 11:F47-F52.
19. Burgisser P., Vernazza P., Flepp M., Boni J., Tomasik Z., Hummel U., et al. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV 1. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2000, 23:138-144.
20. Pascual A., Cachafeiro A., Funk M.L., Fiscus S.A. Comparison of an assay using signal amplification of the heat dissociated p24 antigen with the Roche Monitor human immunodeficiency virus RNA assay. J Clin Microbiol 2002, 40:2472-2475.
21. Schüpbach J., Böni J., Bisset L.R., Tomasik Z., Fischer M., Günthard H.F., et al. HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 33(3):292-299.
22. Basson A.E., Ntsala M., Martinson N., Tlale E., Corrigan G.E., Shao X., et al. Development of phenotypic HIV 1 drug resistance after exposure to single dose nevirapine. J Acquir Immune Defic Syndr 2008.
23. Napravnik S., Cachafeiro A., Stewart P., Eron J.J., Fiscus S.A. HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. J Clin Virol 2009, [Epub ahead of print, PMID: 19896416].
24. Shao X.W., Malmsten A., Lennerstrand J., Sonnerborg A., Unge T., Gronowitz J.S., et al. Use of HIV 1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing. AIDS 2003, 17:1463-1471.
25. Alston B, Mitsuyasu R, Lertora J, Flexner C, Timpone J, van der Horst C. Phase I study of sCd4 PE40 in HIV infected persons: (ACTG 201). In: Int Conf AIDS, June 6-11, vol. 9; 1993. p. 498 [abstract no. PO B29 2178].
26. Fiscus S., Wathen L., Alston B., Flexner C., Kumar P., Lertura J., et al. Safety and toxicity of soluble CD4 Pseudomonas exotoxin 40 in HIV infected individuals. 2nd national conference on human retroviruses and related infections 1995, 1995.
27. Eron J.J., Bosch R.J., Bettendorf D., Petch L., Fiscus S.A., Frank I. The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine. J Acquir Immune Defic Syndr 2007, 45:249-251.
28. Frank I., Bosch R.J., Fiscus S.A., Valentine F., Flexner C., Segal Y., et al. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral naive and experienced HIV type 1 infected subjects: a randomized, placebo controlled trial, ACTG 307. AIDS Res Hum Retroviruses 2004, 20:916-926.
29. Hughes J.P. Mixed effects models with censored data with application to HIV RNA levels. Biometrics 1999, 55(2):625-629.
30. Muller K.E., Stewart P.W. Linear model theory: univariate, multivariate, and mixed models 2006, Wiley Interscience, NY, 410pp.
31. Thiebaut R., Jacqmin-Gadda H. Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed 2003, 74:255-260.
32. Little R.J., Rubin D.B. Statistical analysis with missing data 2002, Wiley Interscience, NY, 408pp. 2nd ed.
33. Liang K.Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
34. http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf.
35. Lee H.H., Dineva M.A., Chua Y.L., Ritchie A.V., Ushiro-Lumb I., Wisiewski C.A. Simple amplification-based assay: a nucleic acid-based point of care platform for HIV-1 testing. J Infect Dis 2010, 201(Suppl. 1):S65-S71.
36. Fiscus S.A., Cheng B., Crowe S., Demeter L., Jennings C., Miller V., et al. HIV viral load assays for resource limited settings - a review. PLoS Med 2006, 3:e417. and the Forum for Collaborative HIV Research Alternative Viral Load Assay Working Group.